|
Report Date : |
26.08.2014 |
IDENTIFICATION DETAILS
|
Name : |
MARTIN DOW LIMITED |
|
|
|
|
Formerly Known As : |
MARTIN DOW PHARMACEUTICALS ( |
|
|
|
|
Registered Office : |
Plot No. 37, Sector 19, Korangi Industrial
Area, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Date of Incorporation : |
06.02.1995 |
|
|
|
|
Com. Reg. No.: |
0034224 |
|
|
|
|
Legal Form : |
Non-Listed Public Limited Company |
|
|
|
|
Line of Business : |
Subject is engaged in manufacture & marketing of pharmaceutical
products. |
|
|
|
|
No of Employees : |
210 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 01, 2014
|
Country Name |
Previous Rating (31.03.2014) |
Current Rating (01.06.2014) |
|
|
B2 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
Decades of internal political
disputes and low levels of foreign investment have led to slow growth and
underdevelopment in
|
Source
: CIA |
MARTIN DOW LIMITED
(FORMERLY: MARTIN
DOW PHARMACEUTICALS (
Registered Address
|
|
Plot No. 37, Sector 19, Korangi Industrial
Area, |
|
Tel # |
92 (21) 111-111-637, 35060551 - 55 (5
Lines) |
|
Fax # |
92 (21) 35060371 |
|
a. |
Nature of Business |
Engaged in
manufacture & marketing of Pharmaceutical Products |
|
b. |
Year Established |
1995 |
|
c. |
Registration # |
0034224 |
In
|
A.F. Ferguson & Co. (Chartered
Accountants) |
|
The Company was incorporated in |
|
Names |
Designation |
|
Mr. M. Jawed Akhai Mr. Muhammad Hanif Mr. Muqtadir M. A. Jawad Mr. Rizwan Omar Mr. Ali Akhai |
Chief Executive Director Director Director Director |
|
Names |
No. of Shares |
|
Mr. M. Jawed Akhai Mrs. Yasmin Jawed Mr. Muqtadir M. A. Jawad Mr. Ali Akhai Mr. Muhammad Hanif Mr. Rizwan Omar |
3,844,550 3,155,250 50 50 50 50 |
Subsidiary
None
Associated Companies
- Do -
COVATINE TABLETS, BONALFA OINTMENT, BON ONE TABLETS, HIOXYL TABLETS, CEANEL CONCENTRATE, FUSIDERM CREAM & OINTMENT, MUSIDIN TABLETS, BIPROFIN TABLETS, TERBIN CREAM & TABLETS, FEXINOL TABLETS & CAPSULES, FUSIDERM - H CREAM, DIATROL, MALCIFER-F, DOWCEF & INSPRA
210
The capacity and production of the company’s
plant is indeterminable as it is multi-product and involves varying processes
of manufacture.
|
Year |
In Pak Rupees |
|
2013 |
3,208,625,504/- |
Various International, Worldwide.
|
Mainly exist at major cities of Pakistan |
1) Habib Metropolitan Bank Limited, Pakistan.
2) National Bank of Pakistan.
3) Habib Bank Limited, Pakistan.
4) Bank Alfalah Limited, Pakistan.
5)
Faysal Bank Limited,
Pakistan.
·
KCCI
·
PPMA
·
FPCCI
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 100.25 |
|
UK Pound |
1 |
Rs. 166.25 |
|
Euro |
1 |
Rs. 133.25 |
Subject Company was established in 1995 and
is engaged in manufacture & marketing of pharmaceutical products. Overall
reputation is satisfactory. Trade relations are reported as fair. Subject can be considered for moderate
business engagements at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.43 |
|
UK Pound |
1 |
Rs.100.12 |
|
Euro |
1 |
Rs.79.74 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared by
: |
SMN |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.